UK Modern Slavery Act Disclosure

This statement is made in accordance with Section 54(1) of the Modern Slavery Act 2015 (the “Act”) and constitutes the Modern Slavery and Human Trafficking Statement for BioCryst UK Limited (“BioCryst”) on behalf of itself and those of its affiliates that are subject to the Act. It relates to the financial year ending 31 December 2024.

BioCryst is a commercial-stage biotech company that is committed to delivering extraordinary medicines that help patients live ordinary lives. With expertise in drug discovery, clinical development, and regulatory affairs, we are advancing clinical programs and generating new compounds from our own discovery engine. We are passionate about advancing novel therapeutics for patients with rare and serious diseases and proud of our culture of engagement and accountability that rewards people for innovative thinking and achievement of key objectives. BioCryst’s US headquarters are located in Durham, North Carolina, our European headquarters in Dublin, Ireland and our Discovery Center of Excellence in Birmingham, Alabama.

BioCryst is committed to upholding a safe work environment and overseeing our operations ethically, lawfully, and to the highest standards of business conduct. Board members, officers and employees are all required to comply with the BioCryst Code of Conduct and Ethics. We require our employees to conduct their scientific and business activities in a manner consistent with the highest ethical, professional and legal standards. Violations of BioCryst’s Code of Conduct and Ethics policies will not be tolerated and will result in disciplinary action, including termination of employment where appropriate.

We expect our employees to utilise our Compliance Hotline to anonymously report any suspected misconduct or unlawful activity. Any such reports shall be properly investigated and resolved. BioCryst believes in the importance of protecting human rights within our global supply chain. Our direct supply chain consists of suppliers located primarily within North America and Western Europe. BioCryst further expects its suppliers to abide by the BioCryst Code of Conduct and Ethics and this includes the obligation to comply with the letter and spirit of all applicable international laws and regulations. The Code of Conduct and Ethics further includes a responsibility for assuring that every employee is welcomed, accepted and rewarded according to his or her contribution. In the past year, we continued to publicise our Code of Conduct and Ethics standards through communications and awareness building with our supplier facing resources with the expectation that they educate and manage our suppliers accordingly. BioCryst shall terminate our relationship with suppliers failing to comply with the standards set forth.

This past year, we continued our practice of visiting a large portion of our direct supply base for general business and quality audit purposes which included interactions with the employees of those suppliers. We routinely examine the organisational structure of the commercial supply chain to maintain visibility, oversight, and interaction with our suppliers. BioCryst is developing steps for further risk management, including the planning of a more robust screening process for current and new suppliers.

BioCryst remains committed to playing our part in preventing any act of modern slavery within our global supply chain.

Luke Robinson
General Manager, UK, Ireland & Nordics
BioCryst UK Limited